{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:46:51Z","timestamp":1794851211921,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258778"],"award-info":[{"award-number":["R01CA258778"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA280317"],"award-info":[{"award-number":["R21CA280317"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA255250"],"award-info":[{"award-number":["R01CA255250"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["V2018-012"],"award-info":[{"award-number":["V2018-012"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute, City of Hope","doi-asserted-by":"publisher","award":["Startup research funding"],"award-info":[{"award-number":["Startup research funding"]}],"id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["EDUC4-12772"],"award-info":[{"award-number":["EDUC4-12772"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-14003"],"award-info":[{"award-number":["TRAN1-14003"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Postdoctoral fellowship"],"award-info":[{"award-number":["Postdoctoral fellowship"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Transformation and Established Investigator Award"],"award-info":[{"award-number":["Transformation and Established Investigator Award"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL138456"],"award-info":[{"award-number":["R01HL138456"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL157280"],"award-info":[{"award-number":["R01HL157280"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["1364-19"],"award-info":[{"award-number":["1364-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59326-9","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:06:13Z","timestamp":1746068773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation"],"prefix":"10.1038","volume":"16","author":[{"given":"Siqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuozi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-7010","authenticated-orcid":false,"given":"Xiaoxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-9123","authenticated-orcid":false,"given":"Guo N.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8207","authenticated-orcid":false,"given":"Christine E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-7467","authenticated-orcid":false,"given":"Irving L.","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3334-9917","authenticated-orcid":false,"given":"Mingye","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"59326_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568\u2013586 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"59326_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"D. G DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"59326_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"J.W Pollard","year":"2004","unstructured":"Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71\u201378 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"59326_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta, L. & Pollard, J. W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887\u2013904 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"59326_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"59326_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"S. K Biswas","year":"2010","unstructured":"Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11, 889\u2013896 (2010).","journal-title":"Nat. Immunol."},{"key":"59326_CR7","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","volume":"41","author":"T Kerzel","year":"2023","unstructured":"Kerzel, T. et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell 41, 1892\u20131910.e10 (2023).","journal-title":"Cancer Cell"},{"key":"59326_CR8","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"S. B Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59326_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"59326_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","volume":"31","author":"S Jaiswal","year":"2010","unstructured":"Jaiswal, S., Chao, M. P., Majeti, R. & Weissman, I. L. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 31, 212\u2013219 (2010).","journal-title":"Trends Immunol"},{"key":"59326_CR11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani, R. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma. N. Engl. J. Med.\u00a0379, 1711\u20131721 (2018).","journal-title":"N. Engl. J. Med."},{"key":"59326_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"B. I Sikic","year":"2019","unstructured":"Sikic, B. I. et al. First-in-human, first-in-class phase i trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. Journal of Clinical Oncology 37, 946\u2013953 (2019).","journal-title":"Journal of Clinical Oncology"},{"key":"59326_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/hum.2016.060","volume":"28","author":"K. W Moyes","year":"2017","unstructured":"Moyes, K. W. et al. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy. Hum. Gene. Ther. 28, 200\u2013215 (2017).","journal-title":"Hum. Gene. Ther."},{"key":"59326_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"59326_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41587-019-0064-8","volume":"37","author":"A Aalipour","year":"2019","unstructured":"Aalipour, A. et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat. Biotechnol. 37, 531\u2013539 (2019).","journal-title":"Nat. Biotechnol."},{"key":"59326_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00262-006-0181-3","volume":"56","author":"D Ritchie","year":"2007","unstructured":"Ritchie, D. et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol. Immunother. 56, 155\u2013163 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"59326_CR17","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/acschembio.8b00509","volume":"13","author":"B. P Joshi","year":"2018","unstructured":"Joshi, B. P., Hardie, J., Mingroni, M. A. & Farkas, M. E. Surface-Modified Macrophages Facilitate Tracking of Breast Cancer-Immune Interactions. ACS Chem. Biol. 13, 2339\u20132346 (2018).","journal-title":"ACS Chem. Biol."},{"key":"59326_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Intracavity generation of glioma stem cell\u2013specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14, 1128 (2022).","journal-title":"Sci. Transl. Med"},{"key":"59326_CR19","doi-asserted-by":"publisher","first-page":"2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang, M. et al. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Advanced Materials 33, 2103258 (2021).","journal-title":"Advanced Materials"},{"key":"59326_CR20","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.nantod.2023.101805","volume":"49","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma. Nano Today 49, 101805 (2023).","journal-title":"Nano Today"},{"key":"59326_CR21","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688","volume":"7","author":"M. A Morrissey","year":"2018","unstructured":"Morrissey, M. A. et al. Chimeric antigen receptors that trigger phagocytosis. Elife 7, e36688 (2018).","journal-title":"Elife"},{"key":"59326_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J. Zhang","year":"2023","unstructured":"Zhang, J. et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports 18, 585\u2013596 (2023).","journal-title":"Stem Cell Reports"},{"key":"59326_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"59326_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2023","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol.\u00a025, 102\u2013116 (2023).","journal-title":"Nat. Immunol."},{"key":"59326_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","volume":"31","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell Stem Cell 31, 1003\u20131019.E9 (2024).","journal-title":"Cell Stem Cell"},{"key":"59326_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah, Z. et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell 31, 803\u2013817.e6 (2024).","journal-title":"Cell Stem Cell"},{"key":"59326_CR27","doi-asserted-by":"crossref","unstructured":"Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N. & June,. C. H. Next-Generation CAR T-cell Therapies. Cancer Discov. 12, 1625\u20131633 (2022).","DOI":"10.1158\/2159-8290.CD-21-1683"},{"key":"59326_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"59326_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 1\u201316 (2021).","journal-title":"Cell"},{"key":"59326_CR30","doi-asserted-by":"publisher","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","volume":"113","author":"JT Sockolosky","year":"2016","unstructured":"Sockolosky, J. T. et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl Acad. Sci. USA 113, E2646\u2013E2654 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59326_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat. Protoc. 14, 756\u2013780 (2019). 2019 14:3.","journal-title":"Nat. Protoc."},{"key":"59326_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311\u2013320 (2015).","journal-title":"MAbs"},{"key":"59326_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443\u2013446 (2000).","journal-title":"Nat. Med."},{"key":"59326_CR34","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1126\/sciadv.abl9171","volume":"8","author":"X Cao","year":"2022","unstructured":"Cao, X. et al. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Sci. Adv. 8, 9171 (2022).","journal-title":"Sci. Adv."},{"key":"59326_CR35","doi-asserted-by":"crossref","unstructured":"Upton, R. et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc. Natl Acad. Sci. USA 118, e2026849118 (2021).","DOI":"10.1073\/pnas.2026849118"},{"key":"59326_CR36","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","volume":"292","author":"M Lo","year":"2017","unstructured":"Lo, M. et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J. Biol. Chem. 292, 3900\u20133908 (2017).","journal-title":"J. Biol. Chem."},{"key":"59326_CR37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature10195","volume":"474","author":"K Hrecka","year":"2011","unstructured":"Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658\u2013661 (2011).","journal-title":"Nature"},{"key":"59326_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1006\/mthe.2001.0329","volume":"3","author":"Y Zhang","year":"2001","unstructured":"Zhang, Y. et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697\u2013707 (2001).","journal-title":"Mol. Ther."},{"key":"59326_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature10071","volume":"472","author":"HS Goodridge","year":"2011","unstructured":"Goodridge, H. S. et al. Activation of the innate immune receptor Dectin-1 upon formation of a \u2018phagocytic synapse\u2019. Nature 472, 471\u2013475 (2011).","journal-title":"Nature"},{"key":"59326_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.abb.2011.02.019","volume":"510","author":"H Park","year":"2011","unstructured":"Park, H., Ishihara, D. & Cox, D. Regulation of tyrosine phosphorylation in macrophage phagocytosis and chemotaxis. Arch. Biochem. Biophys. 510, 101\u2013111 (2011).","journal-title":"Arch. Biochem. Biophys."},{"key":"59326_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2005.02.002","volume":"26","author":"G Berton","year":"2005","unstructured":"Berton, G., M\u00f3csai, A. & Lowell, C. A. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol. 26, 208\u2013214 (2005).","journal-title":"Trends Immunol."},{"key":"59326_CR42","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 75, 3596\u20133607 (2015).","journal-title":"Cancer Res."},{"key":"59326_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"59326_CR44","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"59326_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature06664","volume":"452","author":"DA Muruve","year":"2008","unstructured":"Muruve, D. A. et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103\u2013107 (2008).","journal-title":"Nature"},{"key":"59326_CR46","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara, T. et al. CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol. Cancer Ther. 20, 1388\u20131399 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"59326_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","volume":"5","author":"F Dammeijer","year":"2017","unstructured":"Dammeijer, F. et al. Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol. Res. 5, 535\u2013546 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"59326_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s40425-019-0697-7","volume":"7","author":"S Paul","year":"2019","unstructured":"Paul, S., Chhatar, S., Mishra, A. & Lal, G. Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor. J. Immunother. Cancer 7, 208 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"59326_CR49","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes, J. M. et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12, 6337 (2020).","journal-title":"Sci. Transl. Med."},{"key":"59326_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"59326_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235\u2013271 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"59326_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"59326_CR53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"59326_CR54","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103\u201311108 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59326_CR55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","volume":"42","author":"JD Beck","year":"2024","unstructured":"Beck, J. D. et al. Long-lasting mRNA-encoded interleukin-2 restores CD8\u2009+\u2009T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 42, 568\u2013582 (2024).","journal-title":"Cancer Cell"},{"key":"59326_CR56","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8\u2009+\u2009T cells in cancer. Cancer Cell 40, 624\u2013638 (2022).","journal-title":"Cancer Cell"},{"key":"59326_CR57","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","volume":"171","author":"MP Piechocki","year":"2003","unstructured":"Piechocki, M. P., Ho, Y.-S., Pilon, S. & Wei, W.-Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787\u20135794 (2003).","journal-title":"J. Immunol."},{"key":"59326_CR58","doi-asserted-by":"crossref","unstructured":"Nikolos, F. et al. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat. Commun. 13, 1\u201316 (2022).","DOI":"10.1038\/s41467-022-29026-9"},{"key":"59326_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1600-065X.2006.00444.x","volume":"213","author":"DH Munn","year":"2006","unstructured":"Munn, D. H. & Mellor, A. L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213, 146\u2013158 (2006).","journal-title":"Immunol. Rev."},{"key":"59326_CR60","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8\u2009+\u2009T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066.e25 (2022).","journal-title":"Cell"},{"key":"59326_CR61","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell 38, 685\u2013700.e8 (2020).","journal-title":"Cancer Cell"},{"key":"59326_CR62","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1084\/jem.20071087","volume":"205","author":"M Kool","year":"2008","unstructured":"Kool, M. et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205, 869\u2013882 (2008).","journal-title":"J. Exp. Med."},{"key":"59326_CR63","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.immuni.2019.04.002","volume":"50","author":"I Mondor","year":"2019","unstructured":"Mondor, I. et al. Lymphatic Endothelial Cells Are Essential Components of the Subcapsular Sinus Macrophage Niche. Immunity 50, 1453 (2019).","journal-title":"Immunity"},{"key":"59326_CR64","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2021","unstructured":"Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b + conventional dendritic cells to promote protective anti-tumor CD8\u2009+\u2009T cell immunity. Immunity 55, 308\u2013323.e9 (2021).","journal-title":"Immunity"},{"key":"59326_CR65","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"59326_CR66","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 Blocks CD8\u2009+\u2009T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell\u00a026, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"59326_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15221","volume":"8","author":"M Nizard","year":"2017","unstructured":"Nizard, M. et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat. Commun. 8, 1\u201311 (2017). 2017 8:1.","journal-title":"Nat. Commun."},{"key":"59326_CR68","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41556-022-01024-5","volume":"24","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8\u2009+\u2009T cells to overcome immunotherapy resistance in cancer. Nat. Cell Biol. 24, 1754\u20131765 (2022).","journal-title":"Nat. Cell Biol."},{"key":"59326_CR69","doi-asserted-by":"publisher","first-page":"e000778","DOI":"10.1136\/jitc-2020-000778","volume":"8","author":"EM Garrido-Martin","year":"2020","unstructured":"Garrido-Martin, E. M. et al. M1 hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J. Immunother. Cancer 8, e000778 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"59326_CR70","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","volume":"16","author":"SN Mueller","year":"2015","unstructured":"Mueller, S. N. & Mackay, L. K. Tissue-resident memory T cells: local specialists in immune defence. Nat. Rev. Immunol. 16, 79\u201389 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"59326_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 1\u201318 (2022).","journal-title":"Nat. Commun."},{"key":"59326_CR72","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2119\/molmed.2011.00129","volume":"17","author":"RJ Medina","year":"2011","unstructured":"Medina, R. J. et al. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol. Med. 17, 1045\u20131055 (2011).","journal-title":"Mol. Med."},{"key":"59326_CR73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1126\/scitranslmed.aau2291","volume":"11","author":"Y Deming","year":"2019","unstructured":"Deming, Y. et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer\u2019s disease risk. Sci. Transl. Med. 11, 21 (2019).","journal-title":"Sci. Transl. Med."},{"key":"59326_CR74","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1002\/eji.200838338","volume":"38","author":"H Liu","year":"2008","unstructured":"Liu, H. et al. The FGL2-Fc\u03b3RIIB pathway: A novel mechanism leading to immunosuppression. Eur. J. Immunol. 38, 3114\u20133126 (2008).","journal-title":"Eur. J. Immunol."},{"key":"59326_CR75","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.4049\/jimmunol.1103760","volume":"188","author":"ME Benoit","year":"2012","unstructured":"Benoit, M. E., Clarke, E. V., Morgado, P., Fraser, D. A. & Tenner, A. J. Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells. J. Immunol. 188, 5682\u20135693 (2012).","journal-title":"J. Immunol."},{"key":"59326_CR76","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma, R. Y., Black, A. & Qian, B. Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 43, 546\u2013563 (2022).","journal-title":"Trends Immunol."},{"key":"59326_CR77","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/2326-6066.CIR-18-0077","volume":"6","author":"DO Adeegbe","year":"2018","unstructured":"Adeegbe, D. O. et al. BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in kras-mutant non-small cell lung cancer. Cancer Immunol. Res. 6, 1234\u20131245 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"59326_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8\u2009+\u2009T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"59326_CR79","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1126\/sciimmunol.abh1873","volume":"7","author":"N Weisshaar","year":"2022","unstructured":"Weisshaar, N. et al. Rgs16 promotes antitumor CD8\u2009+\u2009T cell exhaustion. Sci. Immunol. 7, 1873 (2022).","journal-title":"Sci. Immunol."},{"key":"59326_CR80","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion\u2019. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"59326_CR81","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. Immunity 51, 840\u2013855.e5 (2019).","journal-title":"Immunity"},{"key":"59326_CR82","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1073\/pnas.1516485113","volume":"113","author":"AP Benechet","year":"2016","unstructured":"Benechet, A. P. et al. T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection. Proc. Natl Acad. Sci. USA 113, 2182\u20132187 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59326_CR83","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.celrep.2017.08.078","volume":"20","author":"BV Kumar","year":"2017","unstructured":"Kumar, B. V. et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921 (2017).","journal-title":"Cell Rep."},{"key":"59326_CR84","doi-asserted-by":"crossref","unstructured":"Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: Tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).","DOI":"10.1126\/sciimmunol.aas9673"},{"key":"59326_CR85","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/ni.2745","volume":"14","author":"CN Skon","year":"2013","unstructured":"Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8\u2009+\u2009T cells. Nat. Immunol. 14, 1285\u20131293 (2013).","journal-title":"Nat. Immunol."},{"key":"59326_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K. et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88\u201391 (2013).","journal-title":"Science"},{"key":"59326_CR87","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","volume":"7","author":"K Weiskopf","year":"2015","unstructured":"Weiskopf, K. & Weissman, I. L. Macrophages are critical effectors of antibody therapies for cancer. MAbs 7, 303\u2013310 (2015).","journal-title":"MAbs"},{"key":"59326_CR88","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood.2022016101","volume":"141","author":"MM Dacek","year":"2023","unstructured":"Dacek, M. M. et al. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker. Blood 141, 2003\u20132015 (2023).","journal-title":"Blood"},{"key":"59326_CR89","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","volume":"7","author":"EC Piccione","year":"2015","unstructured":"Piccione, E. C. et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7, 946\u2013956 (2015).","journal-title":"MAbs"},{"key":"59326_CR90","doi-asserted-by":"publisher","first-page":"109587","DOI":"10.1016\/j.celrep.2021.109587","volume":"36","author":"EC Suter","year":"2021","unstructured":"Suter, E. C. et al. Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation. Cell Rep. 36, 109587 (2021).","journal-title":"Cell Rep."},{"key":"59326_CR91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S. et al. CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"59326_CR92","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"59326_CR93","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.immuni.2017.07.019","volume":"47","author":"M Baratin","year":"2017","unstructured":"Baratin, M. et al. T Cell Zone Resident Macrophages Silently Dispose of Apoptotic Cells in the Lymph Node. Immunity 47, 349\u2013362.e5 (2017).","journal-title":"Immunity"},{"key":"59326_CR94","doi-asserted-by":"publisher","first-page":"109273","DOI":"10.1016\/j.celrep.2021.109273","volume":"35","author":"K Yu","year":"2021","unstructured":"Yu, K. et al. Targeted delivery of regulatory macrophages to lymph nodes interferes with T cell priming by preventing the formation of stable immune synapses. Cell Rep. 35, 109273 (2021).","journal-title":"Cell Rep."},{"key":"59326_CR95","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.20030448","volume":"198","author":"A Mart\u00edn-Fontecha","year":"2003","unstructured":"Mart\u00edn-Fontecha, A. et al. Regulation of Dendritic Cell Migration to the Draining Lymph Node: Impact on T Lymphocyte Traffic and Priming. J. Exp. Med. 198, 615 (2003).","journal-title":"J. Exp. Med."},{"key":"59326_CR96","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","volume":"55","author":"BW MacNabb","year":"2022","unstructured":"MacNabb, B. W. et al. Dendritic cells can prime anti-tumor CD8\u2009+\u2009T cell responses through major histocompatibility complex cross-dressing. Immunity 55, 982\u2013997.e8 (2022).","journal-title":"Immunity"},{"key":"59326_CR97","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/85438","volume":"7","author":"J Wolfers","year":"2001","unstructured":"Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297\u2013303 (2001).","journal-title":"Nat. Med."},{"key":"59326_CR98","doi-asserted-by":"crossref","unstructured":"Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 184, 2033\u20132052.e21 (2021).","DOI":"10.1016\/j.cell.2021.02.048"},{"key":"59326_CR99","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","volume":"39","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell 39, 1361\u20131374.e9 (2021).","journal-title":"Cancer Cell"},{"key":"59326_CR100","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41590-018-0114-2","volume":"19","author":"D Amsen","year":"2018","unstructured":"Amsen, D., Van Gisbergen, K. P. J. M., Hombrink, P. & Van Lier, R. A. W. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat. Immunol. 19, 538\u2013546 (2018).","journal-title":"Nat. Immunol."},{"key":"59326_CR101","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/0008-5472.CAN-21-4084","volume":"82","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8\u2009+\u2009T Cells and Antitumor Immunity. Cancer Res. 82, 3130\u20133142 (2022).","journal-title":"Cancer Res."},{"key":"59326_CR102","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy, B. et al. Intratumoral CD8\u2009+\u2009T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41, 585\u2013601 (2023).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59326-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59326-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59326-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:28:42Z","timestamp":1746505722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59326-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59326"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59326-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C., S.T.R., and M.F. filed a US patent 63\/431,575, \u201cCompositions Comprising Myeloid Phagocytic Cells Expressing A Chimeric Antigen Receptor\u201d. I.L.W. is a cofounder, director, stockholder in and consultant for Forty Seven (but not Gilead). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4069"}}